Last update 01 Nov 2024

HLN601

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
注射用HLN601脂质体
Target-
Mechanism-
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]
Active Indication
Breast CancerColorectal CancerPancreatic Cancer
Inactive Indication-
Originator Organization
Hongliang (Shanghai) Biomedical Technology Co., Ltd.
Active Organization
Zhongke Bohai Rim (Yantai) Advanced Institute of Pharmaceutical Sciences Co., Ltd.Hongliang (Shanghai) Biomedical Technology Co., Ltd.Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
Inactive Organization-
Drug Highest PhaseIND Approval
First Approval Date-
Regulation-
Login to view timeline

Related

100 Clinical Results associated with HLN601
Login to view more data
100 Translational Medicine associated with HLN601
Login to view more data
100 Patents (Medical) associated with HLN601
Login to view more data
100 Deals associated with HLN601
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerIND Approval
CN
Hongliang (Shanghai) Biomedical Technology Co., Ltd.
26 Feb 2024
Breast CancerIND Approval
CN
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
26 Feb 2024
Breast CancerIND Approval
CN
Zhongke Bohai Rim (Yantai) Advanced Institute of Pharmaceutical Sciences Co., Ltd.
26 Feb 2024
Colorectal CancerIND Approval
CN
Zhongke Bohai Rim (Yantai) Advanced Institute of Pharmaceutical Sciences Co., Ltd.
26 Feb 2024
Colorectal CancerIND Approval
CN
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
26 Feb 2024
Colorectal CancerIND Approval
CN
Hongliang (Shanghai) Biomedical Technology Co., Ltd.
26 Feb 2024
Pancreatic CancerIND Approval
CN
Shanghai Institute of Materia Medica Chinese Academy of SciShanghai Institute of Materia Medica Chinese Academy of Sci
26 Feb 2024
Pancreatic CancerIND Approval
CN
Hongliang (Shanghai) Biomedical Technology Co., Ltd.
26 Feb 2024
Pancreatic CancerIND Approval
CN
Zhongke Bohai Rim (Yantai) Advanced Institute of Pharmaceutical Sciences Co., Ltd.
26 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free